Form 4: Alnylam Pharmaceuticals Director Phillip A. Sharp Executes Stock Option and Sells Shares

Director Phillip A. Sharp exercised stock options and sold shares of Alnylam Pharmaceuticals on February 29, 2024, under a pre-arranged trading plan.

Summary

• On February 29, 2024, Phillip A. Sharp, a director of Alnylam Pharmaceuticals, exercised stock options to acquire 30,000 shares of common stock at a price of $59.25 per share.
• Simultaneously, Sharp sold a total of 30,000 shares of Alnylam common stock in multiple transactions at weighted average prices ranging from $150.60 to $156.54.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 16, 2023.
• Following these transactions, Sharp directly owns no shares and indirectly owns 266,899 shares through a trust.
• The exercised options were set to expire on June 4, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, which is a standard practice in the pharmaceutical industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates